Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$130.79 -2.5%	$117.41	$62.50 ▼ $148.83	$11.40B	0.87	1.56 million shs	332,553 shs
ALMS Alumis	$28.78 -4.2%	$24.25	$3.33 ▼ $31.35	$3.67B	-0.73	2.11 million shs	258,093 shs
AXSM Axsome Therapeutics	$240.05 +1.3%	$238.71	$96.09 ▼ $260.19	$12.32B	0.6	773,763 shs	181,370 shs
ELAN Elanco Animal Health	$25.79 +1.2%	$23.78	$13.39 ▼ $27.72	$12.89B	1.68	5.29 million shs	1.54 million shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	+1.97%	-0.61%	+35.24%	+15.60%	+1,222.39%
ALMS Alumis	+7.40%	+10.15%	+28.36%	+16.07%	+805.12%
AXSM Axsome Therapeutics	+6.91%	+0.72%	-5.41%	+27.11%	+116.04%
ELAN Elanco Animal Health	+1.12%	-0.41%	+5.15%	+13.19%	+73.58%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$130.79 -2.5%	$117.41	$62.50 ▼ $148.83	$11.40B	0.87	1.56 million shs	332,553 shs
ALMS Alumis	$28.78 -4.2%	$24.25	$3.33 ▼ $31.35	$3.67B	-0.73	2.11 million shs	258,093 shs
AXSM Axsome Therapeutics	$240.05 +1.3%	$238.71	$96.09 ▼ $260.19	$12.32B	0.6	773,763 shs	181,370 shs
ELAN Elanco Animal Health	$25.79 +1.2%	$23.78	$13.39 ▼ $27.72	$12.89B	1.68	5.29 million shs	1.54 million shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	+1.97%	-0.61%	+35.24%	+15.60%	+1,222.39%
ALMS Alumis	+7.40%	+10.15%	+28.36%	+16.07%	+805.12%
AXSM Axsome Therapeutics	+6.91%	+0.72%	-5.41%	+27.11%	+116.04%
ELAN Elanco Animal Health	+1.12%	-0.41%	+5.15%	+13.19%	+73.58%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX Abivax	2.81	Moderate Buy	$148.54	13.57% Upside
ALMS Alumis	2.83	Moderate Buy	$40.30	40.05% Upside
AXSM Axsome Therapeutics	2.91	Moderate Buy	$261.48	8.92% Upside
ELAN Elanco Animal Health	2.77	Moderate Buy	$28.55	10.68% Upside

Current Analyst Ratings Breakdown

Latest ALMS, ELAN, AXSM, and ABVX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/20/2026	AXSM Axsome Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$310.00
7/20/2026	AXSM Axsome Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/20/2026	AXSM Axsome Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/17/2026	ABVX Abivax	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	AXSM Axsome Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$290.00
7/9/2026	ABVX Abivax	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$165.00 ➝ $175.00
7/8/2026	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$290.00
7/7/2026	ALMS Alumis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/7/2026	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$302.00 ➝ $304.00
7/2/2026	ABVX Abivax	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$135.00 ➝ $155.00

(Data available from 7/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX Abivax	N/A	N/A	N/A	N/A	$6.57 per share	N/A
ALMS Alumis	$8.40M	436.63	N/A	N/A	$2.88 per share	9.99
AXSM Axsome Therapeutics	$638.50M	19.35	N/A	N/A	$1.75 per share	137.17
ELAN Elanco Animal Health	$4.89B	2.63	$2.38 per share	10.83	$13.18 per share	1.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX Abivax	-$380.27M	-$5.21	N/A	N/A	N/A	N/A	-99.02%	-70.26%	9/14/2026 (Estimated)
ALMS Alumis	-$243.32M	-$1.98	N/A	N/A	N/A	-2,825.70%	-88.79%	-70.72%	8/12/2026 (Estimated)
AXSM Axsome Therapeutics	-$183.17M	-$3.73	N/A	59.13	N/A	-26.59%	-267.16%	-28.53%	8/10/2026 (Estimated)
ELAN Elanco Animal Health	-$232M	-$0.50	N/A	20.80	1.64	-4.95%	7.42%	3.66%	8/5/2026 (Estimated)

Latest ALMS, ELAN, AXSM, and ABVX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ALMS Alumis	-$0.70	N/A	N/A	N/A	$3.62 million	N/A
8/10/2026	Q2 2026	AXSM Axsome Therapeutics	-$0.8919	N/A	N/A	N/A	$221.21 million	N/A
8/5/2026	Q2 2026	ELAN Elanco Animal Health	$0.27	N/A	N/A	N/A	$1.31 billion	N/A
5/22/2026	Q1 2026	ABVX Abivax	-$0.9359	-$0.71	+$0.2259	-$0.71	$0.40 million	$1.56 million
5/14/2026	Q1 2026	ALMS Alumis	-$0.7318	-$0.74	-$0.0082	-$0.74	$2.10 million	$1.74 million
5/6/2026	Q1 2026	ELAN Elanco Animal Health	$0.34	$0.40	+$0.06	$0.11	$1.28 billion	$1.37 billion
5/4/2026	Q1 2026	AXSM Axsome Therapeutics	-$0.85	-$1.26	-$0.41	-$1.26	$191.10 million	$191.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX Abivax	N/A	N/A	N/A	N/A	N/A
ALMS Alumis	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX Abivax	N/A	8.25	8.25
ALMS Alumis	N/A	7.51	7.51
AXSM Axsome Therapeutics	2.27	1.39	1.32
ELAN Elanco Animal Health	0.60	2.16	1.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX Abivax	47.91%
ALMS Alumis	N/A
AXSM Axsome Therapeutics	81.49%
ELAN Elanco Animal Health	97.48%

Insider Ownership

Company	Insider Ownership
ABVX Abivax	N/A
ALMS Alumis	33.70%
AXSM Axsome Therapeutics	20.60%
ELAN Elanco Animal Health	1.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX Abivax	61	87.16 million	N/A	Not Optionable
ALMS Alumis	N/A	127.49 million	84.53 million	N/A
AXSM Axsome Therapeutics	380	51.46 million	40.86 million	Optionable
ELAN Elanco Animal Health	9,400	499.45 million	493.76 million	Optionable

ALMS, ELAN, AXSM, and ABVX Headlines

Recent News About These Companies

Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Kills Ticks¹ Faster² than Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) and NexGard® Plus (afoxolaner, moxidectin, and pyrantel chewable tablets)

July 22 at 6:27 AM | prnewswire.com

Elanco Animal Health Incorporated $ELAN Shares Sold by Bank of New York Mellon Corp

July 22 at 3:28 AM | marketbeat.com

Dimensional Fund Advisors LP Has $586.92 Million Stock Holdings in Elanco Animal Health Incorporated $ELAN

July 21 at 3:59 AM | marketbeat.com

Jennison Associates LLC Purchases 494,216 Shares of Elanco Animal Health Incorporated $ELAN

July 20 at 5:11 AM | marketbeat.com

Principal Financial Group Inc. Grows Stock Holdings in Elanco Animal Health Incorporated $ELAN

July 20 at 4:40 AM | marketbeat.com

472,814 Shares in Elanco Animal Health Incorporated $ELAN Purchased by Dorsey Wright & Associates

July 18, 2026 | marketbeat.com

Allspring Global Investments Holdings LLC Acquires New Shares in Elanco Animal Health Incorporated $ELAN

July 18, 2026 | marketbeat.com

Geneos Wealth Management Inc. Purchases 196,884 Shares of Elanco Animal Health Incorporated $ELAN

July 17, 2026 | marketbeat.com

National Advertising Division Finds Certain PetIQ Claims Supported; Recommends Other Comparative Claims Be Modified or Discontinued

July 16, 2026 | markets.businessinsider.com

Fifth Third Bancorp Grows Holdings in Elanco Animal Health Incorporated $ELAN

July 16, 2026 | marketbeat.com

Will Elanco Animal Health (ELAN) Beat Estimates Again in Its Next Earnings Report?

July 15, 2026 | zacks.com

Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Rating of "Moderate Buy" from Analysts

July 14, 2026 | americanbankingnews.com

Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Recommendation of "Moderate Buy" by Brokerages

July 14, 2026 | marketbeat.com

Elanco Confirms Date and Conference Call for Second Quarter 2026 Financial Results Announcement

July 8, 2026 | tmcnet.com

Integrated Advisors Network LLC Purchases New Position in Elanco Animal Health Incorporated $ELAN

July 7, 2026 | marketbeat.com

Strs Ohio Grows Position in Elanco Animal Health Incorporated $ELAN

July 7, 2026 | marketbeat.com

SG Americas Securities LLC Reduces Stock Position in Elanco Animal Health Incorporated $ELAN

July 6, 2026 | marketbeat.com

Is the Options Market Predicting a Spike in Elanco Animal Health Stock?

June 30, 2026 | zacks.com

Elanco commits to helping producers against NWS

June 29, 2026 | hpj.comH

Louisiana State Employees Retirement System Buys New Shares in Elanco Animal Health Incorporated $ELAN

June 28, 2026 | marketbeat.com

Elanco working to manage parasitic fly’s arrival in U.S.

June 26, 2026 | ibj.comI

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ALMS, ELAN, AXSM, and ABVX Company Descriptions

Abivax NASDAQ:ABVX

$130.78 -3.31 (-2.46%)

As of 12:21 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Alumis NASDAQ:ALMS

$28.78 -1.28 (-4.24%)

As of 12:21 PM Eastern

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Axsome Therapeutics NASDAQ:AXSM

$240.05 +3.10 (+1.31%)

As of 12:21 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Elanco Animal Health NYSE:ELAN

$25.79 +0.31 (+1.22%)

As of 12:21 PM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALMS, ELAN, AXSM, and ABVX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALMS, ELAN, AXSM, and ABVX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALMS, ELAN, AXSM, and ABVX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALMS, ELAN, AXSM, and ABVX Company Descriptions

Abivax NASDAQ:ABVX

Alumis NASDAQ:ALMS

Axsome Therapeutics NASDAQ:AXSM

Elanco Animal Health NYSE:ELAN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALMS, ELAN, AXSM, and ABVX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALMS, ELAN, AXSM, and ABVX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALMS, ELAN, AXSM, and ABVX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALMS, ELAN, AXSM, and ABVX Company Descriptions

Abivax NASDAQ:ABVX

Alumis NASDAQ:ALMS

Axsome Therapeutics NASDAQ:AXSM

Elanco Animal Health NYSE:ELAN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools